Brief: Kineta Reports Response Data Of Ongoing Vista-101 Clinical Trial At AACR 2024

Kineta

08/04/2024 21:19

April 8 (Reuters) - Kineta Inc  KA.O :
    * KINETA REPORTS INITIAL CLINICAL RESPONSE DATA AT AACR 2024
OF
ITS ONGOING PHASE 1/2 VISTA-101 CLINICAL TRIAL
    * KINETA REPORTS INITIAL CLINICAL RESPONSE DATA AT AACR 2024
OF
ITS ONGOING PHASE 1/2 VISTA-101 CLINICAL TRIAL
    * KINETA INC - PARTIAL RESPONSE AND STABLE DISEASE REPORTED
IN
COMBINATION COHORT, AND DURABLE STABLE DISEASE OBSERVED IN
MONOTHERAPY COHORTS
    * KINETA INC - HAS SUSPENDED NEW PATIENT ENROLLMENT INTO
PHASE 1/2
VISTA-101 TRIAL
    * KINETA INC - KVA12123 WAS WELL TOLERATED WITH NO DOSE
LIMITING
TOXICITIES (DLT) OR CYTOKINE RELATED ADVERSE EVENTS AT ANY DOSE
LEVEL
    * KINETA INC - FAVORABLE CLINICAL SAFETY AND TOLERABILITY
PROFILE
OBSERVED WITH NO DOSE LIMITING TOXICITIES
    * KINETA INC - NO EVIDENCE OF CRS-ASSOCIATED CYTOKINES
OBSERVED AT
ANY DOSE LEVEL

Source text for Eikon:  ID:nGNXb6L04X 
Further company coverage:  KA.O 

 ((Reuters.Briefs@thomsonreuters.com;))